vs
MIMEDX GROUP, INC.（MDXG）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是MIMEDX GROUP, INC.的1.8倍（$217.4M vs $118.1M），MIMEDX GROUP, INC.净利率更高（12.9% vs 1.4%，领先11.4%），MIMEDX GROUP, INC.同比增速更快（27.1% vs 0.5%），过去两年MIMEDX GROUP, INC.的营收复合增速更高（18.1% vs 3.0%）
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
MDXG vs RPD — 直观对比
营收规模更大
RPD
是对方的1.8倍
$118.1M
营收增速更快
MDXG
高出26.6%
0.5%
净利率更高
MDXG
高出11.4%
1.4%
两年增速更快
MDXG
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.1M | $217.4M |
| 净利润 | $15.2M | $3.1M |
| 毛利率 | 83.9% | 68.9% |
| 营业利润率 | 17.8% | 1.0% |
| 净利率 | 12.9% | 1.4% |
| 营收同比 | 27.1% | 0.5% |
| 净利润同比 | 104.2% | 44.1% |
| 每股收益（稀释后） | $0.10 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDXGRPD
| Q4 25 | $118.1M | $217.4M | ||
| Q3 25 | $113.7M | $218.0M | ||
| Q2 25 | $98.6M | $214.2M | ||
| Q1 25 | $88.2M | $210.3M | ||
| Q4 24 | $92.9M | $216.3M | ||
| Q3 24 | $84.1M | $214.7M | ||
| Q2 24 | $87.2M | $208.0M | ||
| Q1 24 | $84.7M | $205.1M |
净利润MDXGRPD
| Q4 25 | $15.2M | $3.1M | ||
| Q3 25 | $16.7M | $9.8M | ||
| Q2 25 | $9.6M | $8.3M | ||
| Q1 25 | $7.0M | $2.1M | ||
| Q4 24 | $7.4M | $2.2M | ||
| Q3 24 | $8.1M | $15.4M | ||
| Q2 24 | $17.6M | $6.5M | ||
| Q1 24 | $9.3M | $1.4M |
毛利率MDXGRPD
| Q4 25 | 83.9% | 68.9% | ||
| Q3 25 | 83.5% | 70.2% | ||
| Q2 25 | 81.1% | 70.6% | ||
| Q1 25 | 81.2% | 71.7% | ||
| Q4 24 | 81.8% | 69.5% | ||
| Q3 24 | 81.8% | 70.6% | ||
| Q2 24 | 83.0% | 70.7% | ||
| Q1 24 | 84.7% | 70.3% |
营业利润率MDXGRPD
| Q4 25 | 17.8% | 1.0% | ||
| Q3 25 | 19.5% | 2.7% | ||
| Q2 25 | 12.5% | 1.6% | ||
| Q1 25 | 9.4% | -0.0% | ||
| Q4 24 | 11.9% | 3.4% | ||
| Q3 24 | 13.3% | 6.0% | ||
| Q2 24 | 26.9% | 2.5% | ||
| Q1 24 | 15.6% | 4.7% |
净利率MDXGRPD
| Q4 25 | 12.9% | 1.4% | ||
| Q3 25 | 14.7% | 4.5% | ||
| Q2 25 | 9.8% | 3.9% | ||
| Q1 25 | 8.0% | 1.0% | ||
| Q4 24 | 8.0% | 1.0% | ||
| Q3 24 | 9.6% | 7.2% | ||
| Q2 24 | 20.2% | 3.1% | ||
| Q1 24 | 10.9% | 0.7% |
每股收益（稀释后）MDXGRPD
| Q4 25 | $0.10 | $0.05 | ||
| Q3 25 | $0.11 | $0.15 | ||
| Q2 25 | $0.06 | $0.13 | ||
| Q1 25 | $0.05 | $0.03 | ||
| Q4 24 | $0.05 | $0.08 | ||
| Q3 24 | $0.05 | $0.21 | ||
| Q2 24 | $0.12 | $0.09 | ||
| Q1 24 | $0.06 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $166.1M | $474.7M |
| 总债务越低越好 | $18.0M | — |
| 股东权益账面价值 | $256.5M | $154.7M |
| 总资产 | $342.7M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MDXGRPD
| Q4 25 | $166.1M | $474.7M | ||
| Q3 25 | $142.1M | $407.1M | ||
| Q2 25 | $118.9M | $511.7M | ||
| Q1 25 | $106.4M | $493.5M | ||
| Q4 24 | $104.4M | $521.7M | ||
| Q3 24 | $88.8M | $443.7M | ||
| Q2 24 | $69.0M | $442.6M | ||
| Q1 24 | $48.5M | $411.7M |
总债务MDXGRPD
| Q4 25 | $18.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $19.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MDXGRPD
| Q4 25 | $256.5M | $154.7M | ||
| Q3 25 | $238.9M | $127.2M | ||
| Q2 25 | $216.6M | $90.4M | ||
| Q1 25 | $202.8M | $52.7M | ||
| Q4 24 | $193.1M | $17.7M | ||
| Q3 24 | $181.0M | $-5.1M | ||
| Q2 24 | $168.0M | $-52.6M | ||
| Q1 24 | $155.7M | $-86.4M |
总资产MDXGRPD
| Q4 25 | $342.7M | $1.7B | ||
| Q3 25 | $319.0M | $1.7B | ||
| Q2 25 | $291.1M | $1.6B | ||
| Q1 25 | $270.4M | $1.6B | ||
| Q4 24 | $263.9M | $1.7B | ||
| Q3 24 | $243.9M | $1.6B | ||
| Q2 24 | $230.2M | $1.5B | ||
| Q1 24 | $221.7M | $1.5B |
负债/权益比MDXGRPD
| Q4 25 | 0.07× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.0M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.4M |
| 自由现金流率自由现金流/营收 | — | 16.8% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 1.64× | 12.01× |
| 过去12个月自由现金流最近4个季度 | — | $146.2M |
8季度趋势，按日历期对齐
经营现金流MDXGRPD
| Q4 25 | $25.0M | $37.6M | ||
| Q3 25 | $29.3M | $39.0M | ||
| Q2 25 | $14.4M | $47.5M | ||
| Q1 25 | $5.3M | $29.8M | ||
| Q4 24 | $18.8M | $63.8M | ||
| Q3 24 | $19.6M | $44.0M | ||
| Q2 24 | $21.8M | $32.9M | ||
| Q1 24 | $6.0M | $31.1M |
自由现金流MDXGRPD
| Q4 25 | — | $36.4M | ||
| Q3 25 | — | $34.8M | ||
| Q2 25 | — | $46.6M | ||
| Q1 25 | — | $28.4M | ||
| Q4 24 | — | $62.6M | ||
| Q3 24 | — | $42.6M | ||
| Q2 24 | — | $32.6M | ||
| Q1 24 | — | $30.4M |
自由现金流率MDXGRPD
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 16.0% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 13.5% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 14.8% |
资本支出强度MDXGRPD
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.3% |
现金转化率MDXGRPD
| Q4 25 | 1.64× | 12.01× | ||
| Q3 25 | 1.75× | 3.97× | ||
| Q2 25 | 1.50× | 5.70× | ||
| Q1 25 | 0.75× | 14.14× | ||
| Q4 24 | 2.53× | 29.36× | ||
| Q3 24 | 2.42× | 2.85× | ||
| Q2 24 | 1.24× | 5.03× | ||
| Q1 24 | 0.65× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
